Related Experiment Video
Updated: Apr 9, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
First Reported Case of Upadacitinib-Associated Cytomegalovirus Viremia and Suspected Pneumonitis in Ulcerative
Wilfredo Jhoel Javier-Rojas1, Alvin Boyd Newman-Caro2, Mamoon Ghellai1
1Department of Internal Medicine, Morsani College of Medicine GME: HCA Florida Blake Hospital, HCA Healthcare/University of South Florida (USF), Bradenton, FL.
Abstract:
Cytomegalovirus (CMV) reactivation is a clinically important risk in patients with inflammatory bowel disease, particularly those receiving systemic immunosuppression or Janus kinase (JAK) inhibitor therapy, which can impair immunity. JAK inhibitors, including upadacitinib, may predispose patients to opportunistic viral infections. We report a patient with moderate ulcerative colitis who developed CMV viremia with suspected CMV pneumonitis 4 weeks after starting upadacitinib. Antiviral therapy led to clinical and virologic resolution. This case broadens the spectrum of CMV-related complications associated with JAK inhibition and underscores the importance of maintaining vigilance for systemic viral reactivation in inflammatory bowel disease patients receiving immunosuppressive therapy.
More Related Videos
06:21Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
04:01Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
Published on: September 8, 2022
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Cytomegalovirus Disease
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Acute Pyelonephritis II: Diagnostic Studies and Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids